Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY-NC 4.0BMJ Open

Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS)

  • Dai Ogata1,2
  • Eiji Nakano1
  • Naoya Yamazaki3
  • Takeru Funakoshi4
  • Akira Takahashi5
  • Ayano Maruyama6
  • Motoki Nakamura7
  • Ryunosuke Machida8
  • Yukari Nagasaka9
  • Kanako Kagatsume9
  • Masako Inaba9
  • Takako Hitomi9
1 more authors
  • Kenjiro Namikawa10
10 affiliations
  1. 1Dermatology, National Cancer Center Japan, Chuo, Tokyo, Japan
  2. 2Dermatology, University of Miyazaki, Miyazaki, Miyazaki Prefecture, Japan
  3. 33 Department of Dermatologic Oncology, National Cancer Center Japan, Chuo-ku, Tokyo, Japan
  4. 4Keio University, Minato, Tokyo, Japan
  5. 5Dermatology, National Cancer Center-Hospital East, Kashiwa, Chiba Prefecture, Japan
  6. 6Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto Prefecture, Japan
  7. 7Dermatology, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Aichi Prefecture, Japan
  8. 8National Cancer Center Japan Center for Research Administration and Support Biostatistics Division, Chuo, Japan
  9. 9Clinical Research Support Office, National Cancer Center Japan, Chuo, Tokyo, Japan
  10. 10Department of Dermatologic Oncology, National Cancer Center Japan, Chuo-ku, Tokyo, Japan
Open at sourcePDFDOICite

Related

  1. Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study
    Chih-Wen Su, Shao-Jing Wang, Yu-Hsiang Shih +9
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  2. A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
    Saki Sueda, Tomokazu Kawaoka, Yasutoshi Fujii +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records
    Canchao Sun, Juan Xu, Tiye Sun
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
    Jordi Remon, Paolo Bironzo, Nicolas Girard +17
    Lancet OncologyPeer-reviewedLicence not statedFull text14 citedNeurologyHAL
  5. Recurrent TFE3-Rearranged Renal Cell Carcinoma Responding to Pembrolizumab Plus Lenvatinib After Postoperative Pembrolizumab: A Case Report.
    Masashi Fujimoto, Tomoyasu Sano, Yuta Sano +7
    IJU case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ogata2026pembrolizumab,
  title = {{Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS)}},
  author = {Dai Ogata and Eiji Nakano and Naoya Yamazaki and Takeru Funakoshi and Akira Takahashi and Ayano Maruyama and Motoki Nakamura and Ryunosuke Machida and Yukari Nagasaka and Kanako Kagatsume and Masako Inaba and Takako Hitomi and Kenjiro Namikawa},
  journal = {BMJ Open},
  year = {2026},
  month = oct,
  doi = {10.1136/bmjopen-2026-120316},
  url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-120316},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS)
AU  - Dai Ogata
AU  - Eiji Nakano
AU  - Naoya Yamazaki
AU  - Takeru Funakoshi
AU  - Akira Takahashi
AU  - Ayano Maruyama
AU  - Motoki Nakamura
AU  - Ryunosuke Machida
AU  - Yukari Nagasaka
AU  - Kanako Kagatsume
AU  - Masako Inaba
AU  - Takako Hitomi
AU  - Kenjiro Namikawa
PY  - 2026
DA  - 2026/10/09
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-120316
UR  - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-120316
SN  - 2044-6055
SN  - 2044-6055
ER  -